Evidence map›Paper›PMID 34455421›Full record

ArticleLeukemia2022

Insights into the mechanisms underlying aberrant SOX11 oncogene expression in mantle cell lymphoma.

Roser Vilarrasa-Blasi, Núria Verdaguer-Dot, Laura Belver, Paula Soler-Vila, Renée Beekman, Vicente Chapaprieta, Marta Kulis, Ana C Queirós, Maribel Parra, María José Calasanz and 8 more

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Towards precision medicine in lymphoid malignancies.Journal of internal medicine · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 7 institutions in 2 countries.

Roser Vilarrasa-BlasiInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. rvilarrasa@clinic.cat.ORCID http://orcid.org/0000-0002-3384-0693
Núria Verdaguer-DotInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Laura BelverInstitute for Cancer Genetics, Columbia University Medical Center, New York, NY, USA.
Paula Soler-VilaCNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
Renée BeekmanInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Vicente ChapaprietaInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.ORCID http://orcid.org/0000-0002-4910-5394
Marta KulisInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Ana C QueirósInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Maribel ParraJosep Carreras Leukaemia Research Institute, IJC Building, Campus ICO-Germans Trias i Pujol, Barcelona, Spain.ORCID http://orcid.org/0000-0002-9072-5763
María José CalasanzÁrea de Oncología, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Universidad de Navarra, Pamplona, Spain.ORCID http://orcid.org/0000-0002-0374-3008
Xabier AgirreÁrea de Oncología, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Universidad de Navarra, Pamplona, Spain.ORCID http://orcid.org/0000-0002-6558-9560
Felipe ProsperÁrea de Oncología, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Universidad de Navarra, Pamplona, Spain.ORCID http://orcid.org/0000-0001-6115-8790
Sílvia BeàInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Dolors ColomerInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.ORCID http://orcid.org/0000-0001-7486-8484
Marc A Marti-RenomCNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
Adolfo FerrandoInstitute for Cancer Genetics, Columbia University Medical Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-6212-8574
Elías CampoInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.ORCID http://orcid.org/0000-0001-9850-9793
José Ignacio Martin-SuberoInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. imartins@clinic.cat.ORCID http://orcid.org/0000-0001-8809-5195
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESHospital Clínic de Barcelona · ESNavarre Institute of Health Research · ESColumbia University Irving Medical Center · USInstitució Catalana de Recerca i Estudis Avançats · ESCentre for Genomic Regulation · ESJosep Carreras Leukaemia Research Institute · ES

Funding

Preclinical Models and Therapeutics CoreP01CA229100 · NCI · MAYO CLINIC ARIZONA · PI INGHIRAMI, GIORGIO · 2018 to 2022
$10.2M
NCI NIH HHS P01 CA229100
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Chromatin Assembly and DisassemblyEnhancer Elements, GeneticPromoter Regions, GeneticHumansLymphoma, Mantle-CellSOXC Transcription FactorsTumor Cells, CulturedSOX11 protein, humanSOXC Transcription Factors

Identifiers

PMID34455421
OpenAlexW3196618600

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.